Who
Benjamin Machinas Beneski
SVP, Chief Technical Officer
Company insider
Files Form 4 as: SVP, Chief Technical Officer, Allogene Therapeutics.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $113K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2025
- Last trade
- 31 Mar 2026
- Last filed
- 2 Apr 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Mar 2026filed 2 Apr 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1682,867 at $2.50 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1682,867 at $2.50 | filing |
| 16 Mar 2026filed 18 Mar 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K4,835 at $2.47 | filing |
| 16 Mar 2026filed 18 Mar 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K4,835 at $2.47 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K7,132 at $2.60 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K7,132 at $2.60 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K7,549 at $1.73 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —373,757 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,720 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —373,757 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,720 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K7,549 at $1.73 | filing |
| 17 Nov 2025filed 19 Nov 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $959786 at $1.22 | filing |
| 14 Mar 2025filed 18 Mar 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K5,488 at $1.98 | filing |
| 1 Mar 2025filed 5 Mar 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,339 at $0.00 | filing |
| 1 Mar 2025filed 5 Mar 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —31,755 at $0.00 | filing |
News
Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026Head to Head Comparison: Generate Biomedicines (NASDAQ:GENB) vs. Allogene Therapeutics (NASDAQ:ALLO)ALLO · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Benjamin Machinas Beneski; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.